Bio-Rad Laboratories, Inc.

Key metrics

Financial performance

Over the last 9 fiscal years Bio-Rad Laboratories, Inc.'s revenue grew from $2.07B to $2.58B, a compound annual growth rate of 2.5%. Net profit margin expanded from 1.3% to 29.4% over the same period - every figure below comes from the company's audited annual filings.

Key statistics

Latest filings

Browse the full filing history (1,494 filings)

Recent press releases

• Bio-Rad to Participate in Upcoming Investor Conferences2026-05-08

  Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences:

• Bio-Rad Reports First-Quarter 2026 Financial Results2026-04-30

  Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the Middle East, reported sales grew 1.1% year-over-year. Against this backdrop, we generated strong operating cash flow, $78 million in free cash flow, and repurchased approximately 176 thousand shares, highlighting the quality and long-term durability of our business. We continue to evaluate and optimize our organization to create more value for customers, and ultimately, shareholders."

• Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 20262026-04-16

  To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

• Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results2026-02-12

  Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market adoption of our expanded ddPCR™ product portfolio. As we enter 2026, we remain committed to improving overall performance.”

Similar companies

The largest companies sharing Bio-Rad Laboratories, Inc.'s SEC industry classification (laboratory analytical instruments).